Results 21 to 30 of about 137,000 (307)

JAK inhibition ameliorates bone destruction by simultaneously targeting mature osteoclasts and their precursors

Inflammation and Regeneration, 2023
Background Rheumatoid arthritis (RA) is characterized by chronic inflammation and resultant cartilage/bone destruction because of aberrantly activated osteoclasts.
Shinya Yari, Junichi Kikuta, Hotaka Shigyo, Yu Miyamoto, Daisuke Okuzaki, Yuki Furusawa, Masafumi Minoshima, Kazuya Kikuchi, Masaru Ishii   +8 more
doaj   +1 more source

JAK inhibitors in autoinflammation [PDF]

Journal of Clinical Investigation, 2018
Interferonopathies are a subset of autoinflammatory disorders with a prominent type I IFN gene signature. Treatment of these patients has been challenging, given the lack of response to common autoinflammatory therapeutics including IL-1 and TNF blockade.
Hal M, Hoffman, Lori, Broderick
openaire   +2 more sources

Insights, current status and future perspective of JAK inhibitors in the treatment of alopecia areata

Pifu-xingbing zhenliaoxue zazhi, 2022
Alopecia areata (AA) is a chronic heterogeneous inflammatory disease, with unknown pathogenesis. Although there are quite a few options to choose for treatment of AA, there is no specific therapic method, and neither is one therapic method for all ...
Xingqi ZHANG
doaj   +1 more source

Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss

Inflammation and Regeneration, 2023
Background The types of bone damage in rheumatoid arthritis (RA) include joint erosion, periarticular osteoporosis, and systemic osteoporosis. Janus kinase (JAK) inhibitors ameliorate inflammation and joint erosion in RA, but their effect on the three ...
Masatsugu Komagamine, Noriko Komatsu, Rui Ling, Kazuo Okamoto, Shi Tianshu, Kotaro Matsuda, Tsutomu Takeuchi, Yuko Kaneko, Hiroshi Takayanagi   +8 more
doaj   +1 more source

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies

Immunological Medicine, 2023
Recent studies have demonstrated that Janus kinase (JAK) plays a crucial role in signal transduction by directly affecting various cytokine receptors involved in inflammatory diseases such as atopic dermatitis (AD).
Toshiaki Kogame, Gyohei Egawa, Kenji Kabashima   +2 more
doaj   +1 more source

JAK inhibitors ∼ overview∼

Immunological Medicine, 2023
Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons. Indeed, recent rapid progress in JAK inhibitors in addition to biological agents provided therapeutic options for various diseases, including immune-mediated ...
openaire   +3 more sources

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials

HemaSphere, 2023
The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF).
Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Miklos Egyed, Uwe Platzbecker, Jiří Mayer, Sebastian Grosicki, Árpád Illés, Tomasz Woźny, Stephen T. Oh, Donal McLornan, Ilya Kirgner, Sung-Soo Yoon, Claire N. Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben Mesa   +19 more
doaj   +1 more source

Topical JAK inhibitor for refractory skin inflammation in STAT1 GOFTopical JAK inhibitor in STAT1 GOF [PDF]

Journal of Human Immunity
Topical ruxolitinib induced rapid and sustained improvement of refractory skin inflammation in a child with STAT1 GOF disease, highlighting its potential in managing localized inflammation in immune dysregulation.
Valentina Guarnieri, Tiphaine Arlabosse, Claire Booth, Gabriela Petrof   +3 more
doaj   +1 more source

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]

, 2018
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T, Ferguson, Ian D, Hann, Byron C, Lam, Christine, Lin, Yu-Hsiu T, Liu, Hui, Liu, Jun O, Mariano, Margarette C, Mitsiades, Constantine S, Murnane, Megan, Smith, Geoffrey A, Taunton, Jack, Wiita, Arun P, Wong, Sandy W   +13 more
core   +2 more sources

JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL. [PDF]

PLoS ONE, 2015
Constitutive activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) axis is fundamental to the molecular pathogenesis of a host of hematological disorders, including acute leukemias and myeloproliferative neoplasms ...
Jun Guo, Lisa Roberts, Zhui Chen, Philip J Merta, Keith B Glaser, O Jameel Shah   +5 more
doaj   +1 more source